- Home
- AURA vs ERAS Comparison
AURA vs ERAS Comparison
Compare AURA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AURA
- ERAS
- Stock Information
- Founded
- AURA 2007
- ERAS 2018
- Country
- AURA United States
- ERAS United States
- Employees
- AURA N/A
- ERAS N/A
- Industry
- AURA Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- AURA Health Care
- ERAS Health Care
- Exchange
- AURA Nasdaq
- ERAS Nasdaq
- Market Cap
- AURA 396.8M
- ERAS 439.7M
- IPO Year
- AURA 2021
- ERAS 2021
- Fundamental
- Price
- AURA $6.04
- ERAS $2.38
- Analyst Decision
- AURA Strong Buy
- ERAS Buy
- Analyst Count
- AURA 5
- ERAS 6
- Target Price
- AURA $21.80
- ERAS $3.67
- AVG Volume (30 Days)
- AURA 302.8K
- ERAS 1.7M
- Earning Date
- AURA 11-13-2025
- ERAS 11-07-2025
- Dividend Yield
- AURA N/A
- ERAS N/A
- EPS Growth
- AURA N/A
- ERAS N/A
- EPS
- AURA N/A
- ERAS N/A
- Revenue
- AURA N/A
- ERAS N/A
- Revenue This Year
- AURA N/A
- ERAS N/A
- Revenue Next Year
- AURA N/A
- ERAS N/A
- P/E Ratio
- AURA N/A
- ERAS N/A
- Revenue Growth
- AURA N/A
- ERAS N/A
- 52 Week Low
- AURA $4.35
- ERAS $1.01
- 52 Week High
- AURA $11.29
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- AURA 48.89
- ERAS 54.81
- Support Level
- AURA $5.62
- ERAS $2.34
- Resistance Level
- AURA $6.60
- ERAS $2.54
- Average True Range (ATR)
- AURA 0.36
- ERAS 0.16
- MACD
- AURA 0.02
- ERAS -0.03
- Stochastic Oscillator
- AURA 45.69
- ERAS 43.16
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.